Previous studies have shown that CDH17 is associated with tumor progression and aggressiveness in various types of GI cancers, including CRC [7], hepatocellular carcinoma [13, 14, 16], gastric cancer [27, 28], and cholangiocarcinoma [12]. Here, CDH17 is linked to cholangiocarcinoma.